Cargando…

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo

The five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained a dismal 9% for approximately 40 years with an urgent need for novel therapeutic interventions. ONC201 is the founding member of the imipridone class, comprised of orally bioavailable small molecules that have shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jhaveri, Aakash V., Zhou, Lanlan, Ralff, Marie D., Lee, Young S., Navaraj, Arunasalam, Carneiro, Benedito A., Safran, Howard, Prabhu, Varun V., Ross, Eric A., Lee, Seulki, El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726623/ https://www.ncbi.nlm.nih.gov/pubmed/34856854 http://dx.doi.org/10.1080/15384047.2021.1976567

Ejemplares similares

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
por: Ray, Jocelyn E., et al.
Publicado: (2021)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

Role of Dopamine Receptors in the Anticancer Activity of ONC201()()
por: Kline, Christina Leah B., et al.
Publicado: (2017)

AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms
por: Wagner, Jessica, et al.
Publicado: (2018)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
por: Prabhu, Varun V., et al.
Publicado: (2017)

Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2016)

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2021)

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2015)

Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2016)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
por: Wagner, Jessica, et al.
Publicado: (2015)

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
por: Allen, Joshua E, et al.
Publicado: (2015)

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
por: Lev, Avital, et al.
Publicado: (2017)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
por: Stein, Mark N., et al.
Publicado: (2019)

Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor()
por: Hayes-Jordan, Andrea A., et al.
Publicado: (2018)

Strategies to sensitize cancer cells to immunotherapy
por: George, Andrew, et al.
Publicado: (2021)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells
por: Zhou, Lanlan, et al.
Publicado: (2020)

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection
por: Zhou, Lanlan, et al.
Publicado: (2020)

TIC10/ONC201: a bend in the road to clinical development
por: Greer, Yoshimi Endo, et al.
Publicado: (2015)

ONC201 kills breast cancer cells in vitro by targeting mitochondria
por: Greer, Yoshimi Endo, et al.
Publicado: (2018)

Mycobacterial tlyA gene product is localized to the cell-wall without signal sequence
por: Kumar, Santosh, et al.
Publicado: (2015)

Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022)

CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis
por: Prabhu, Varun V., et al.
Publicado: (2012)

SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
por: Odia, Yazmin, et al.
Publicado: (2022)

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
por: De Souza, Andre, et al.
Publicado: (2020)

GASS-tly side effects: antipsychotic monitoring for inpatients across NHS Lanarkshire
por: Paton, Cristina, et al.
Publicado: (2021)

ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression
por: Dwucet, Annika, et al.
Publicado: (2021)

Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor
por: Anderson, Peter M., et al.
Publicado: (2022)

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy
por: Gardner, Sharon L, et al.
Publicado: (2022)

Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues
por: Graves, Paul R., et al.
Publicado: (2019)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
por: Tu, Yong-sheng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gvqo3s4nj01t9n22d955prko48